Benjamin Edwards Inc. Has $27.57 Million Stock Holdings in STERIS plc (NYSE:STE)

Benjamin Edwards Inc. raised its holdings in STERIS plc (NYSE:STE - Free Report) by 2,123.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 113,672 shares of the medical equipment provider's stock after purchasing an additional 108,559 shares during the quarter. Benjamin Edwards Inc. owned approximately 0.12% of STERIS worth $27,574,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of STE. Atom Investors LP lifted its position in STERIS by 37.8% during the 3rd quarter. Atom Investors LP now owns 3,716 shares of the medical equipment provider's stock worth $901,000 after buying an additional 1,020 shares in the last quarter. Aureus Asset Management LLC raised its stake in shares of STERIS by 0.4% in the third quarter. Aureus Asset Management LLC now owns 30,516 shares of the medical equipment provider's stock worth $7,401,000 after acquiring an additional 116 shares during the last quarter. Eventide Asset Management LLC lifted its position in shares of STERIS by 8.6% during the third quarter. Eventide Asset Management LLC now owns 143,459 shares of the medical equipment provider's stock worth $34,795,000 after purchasing an additional 11,362 shares in the last quarter. Public Sector Pension Investment Board lifted its position in shares of STERIS by 13.2% during the third quarter. Public Sector Pension Investment Board now owns 4,283 shares of the medical equipment provider's stock worth $1,039,000 after purchasing an additional 500 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of STERIS by 2.5% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,253 shares of the medical equipment provider's stock valued at $10,491,000 after purchasing an additional 1,053 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company's stock.

Insider Activity

In other news, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $217.32, for a total value of $365,532.24. Following the sale, the senior vice president now directly owns 11,372 shares in the company, valued at $2,471,363.04. This trade represents a 12.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael J. Tokich sold 23,332 shares of the business's stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the sale, the chief financial officer now directly owns 42,930 shares in the company, valued at approximately $10,603,710. This represents a 35.21 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company's stock.

STERIS Trading Down 0.1 %

Shares of STERIS stock traded down $0.20 during trading on Monday, hitting $218.86. 606,878 shares of the company were exchanged, compared to its average volume of 497,823. The firm has a market capitalization of $21.60 billion, a P/E ratio of 49.90 and a beta of 0.85. The firm's fifty day moving average price is $225.01 and its 200 day moving average price is $228.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 1.55. STERIS plc has a 1-year low of $195.50 and a 1-year high of $248.24.

STERIS (NYSE:STE - Get Free Report) last issued its earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating the consensus estimate of $2.12 by $0.02. The firm had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The business's quarterly revenue was up 7.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.03 earnings per share. As a group, sell-side analysts expect that STERIS plc will post 9.15 earnings per share for the current fiscal year.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th will be issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 1.04%. The ex-dividend date is Tuesday, November 19th. STERIS's dividend payout ratio (DPR) is presently 52.05%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. JMP Securities reaffirmed a "market outperform" rating and set a $265.00 price objective on shares of STERIS in a report on Monday, November 18th. Piper Sandler raised STERIS from a "neutral" rating to an "overweight" rating and upped their price target for the company from $230.00 to $260.00 in a research note on Thursday, October 24th. Stephens reiterated an "overweight" rating and issued a $260.00 price objective on shares of STERIS in a research report on Thursday, November 7th. Needham & Company LLC restated a "hold" rating on shares of STERIS in a research report on Friday, November 8th. Finally, StockNews.com lowered shares of STERIS from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, October 29th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $253.00.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.